Business Case

Mapped treatment landscape for a rare ophthalmology indication in APAC for a mid-sized pharmaceutical company, including eligible patient population and pricing levels

Our client, a mid-sized pharmaceutical company, sought to understand the investments and potential return of a rare ophthalmologic indication in APAC. As a rare indication, our client anticipated a hyper-targeted launch. LSC was able to map the treatment landscape, analyze pricing and develop a strategic investment strategy in each country, ultimately allowing our client to prioritize investment by target market, but also realize synergies between markets where possible.